FOUNDATIONONE®LIQUID CDx

PATIENT
Hsu, Hsiu-Chu

TUMOR TYPE
Liver cholangiocarcinoma
COUNTRY CODE
TW

REPORT DATE
06 Mar 2022
ORDERED TEST #
ORD-1310401-01

ABOUT THE TEST FoundationOne®Liquid CDx is a next generation sequencing (NGS) assay that identifies clinically relevant genomic alterations in circulating cell-free DNA.

PATIENT
DISEASE Liver cholangiocarcinoma
NAME Hsu, Hsiu-Chu
DATE OF BIRTH 01 August 1949
SEX Female
MEDICAL RECORD # 28253476

PHYSICIAN
ORDERING PHYSICIAN Yeh, Yi-Chen
MEDICAL FACILITY Taipei Veterans General Hospital
ADDITIONAL RECIPIENT None
MEDICAL FACILITY ID 205872
PATHOLOGIST Not Provided

SPECIMEN
SPECIMEN ID H-CH 8/1/1949
SPECIMEN TYPE Blood
DATE OF COLLECTION 23 February 2022
SPECIMEN RECEIVED 25 February 2022

Biomarker Findings

Blood Tumor Mutational Burden - 1 Muts/Mb
Microsatellite status - MSI-High Not Detected
Tumor Fraction - Elevated Tumor Fraction

Genomic Findings

For a complete list of the genes assayed, please refer to the Appendix.

FGFR2 FGFR2-BICC1 fusion
ARID1A S460fs*163
TP53 P151S

† See About the Test in appendix for details.

Report Highlights

- Targeted therapies with **NCCN categories of evidence** in this tumor type: **Infigratinib** (p. 8), **Pemigatinib** (p. 8)
- Evidence-matched **clinical trial options** based on this patient's genomic findings: (p. 10)

BIOMARKER FINDINGS	THERAPY AND CLINICAL TRIAL IMPLICATIONS
Blood Tumor Mutational Burden - 1 Muts/Mb	**No therapies or clinical trials.** See Biomarker Findings section
Microsatellite status - MSI-High Not Detected	**MSI-High not detected. No evidence of microsatellite instability in this sample (see Appendix section).**
Tumor Fraction - Elevated Tumor Fraction	**Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected. There is higher sensitivity for identifying genomic alterations and a lower risk of false negative results in specimens with elevated tumor fraction; the positive percent agreement observed between liquid and tissue for defined short variants is ≥ 90% (Li et al., 2021; AACR Abstract 2231) (see Biomarker Findings section).**

GENOMIC FINDINGS		VAF %	THERAPIES WITH CLINICAL RELEVANCE (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL RELEVANCE (IN OTHER TUMOR TYPE)
FGFR2 -	FGFR2-BICC1 fusion	28.1%	Infigratinib 2A	Erdafitinib
			Pemigatinib 2A	
10 Trials see p. 12				
ARID1A -	S460fs*163	12.2%	None	None
8 Trials see p. 10				

2A *NCCN category*

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENOMIC FINDINGS WITH NO REPORTABLE THERAPEUTIC OR CLINICAL TRIAL OPTIONS

For more information regarding biological and clinical significance, including prognostic, diagnostic, germline, and potential chemosensitivity implications, see the Genomic Findings section.

NOTE Genomic alterations detected may be associated with activity of certain approved therapies; however, the therapies listed in this report may have varied clinical evidence in the patient's tumor type. Therapies and the clinical trials listed in this report may not be complete and/or exhaustive. Neither the therapies nor the trials identified are ranked in order of potential or predicted efficacy for this patient, nor are they ranked in order of level of evidence for this patient's tumor type. This report should be regarded and used as a supplementary source of information and not as the single basis for the making of a therapy decision. All treatment decisions remain the full and final responsibility of the treating physician and physicians should refer to approved prescribing information for all therapies. Therapies contained in this report may have been approved by the US FDA or other national authorities; however, they might not have been approved in your respective country. In the appropriate clinical context, germline testing of *APC*, *ATM*, *BAP1*, *BRCA1*, *BRCA2*, *BRIP1*, *CHEK2*, *FH*, *FLCN*, *MEN1*, *MLH1*, *MSH2*, *MSH6*, *MUTYH*, *NF1*, *NF2*, *PALB2*, *PMS2*, *POLE*, *PTEN*, *RAD51C*, *RAD51D*, *RB1*, *RET*, *SDHA*, *SDHB*, *SDHC*, *SDHD*, *SMAD4*, *STK11*, *TGFBR2*, *TP53*, *TSC1*, *TSC2*, *VHL*, and *WT1* is recommended.

Variant Allele Frequency is not applicable for copy number alterations.

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531



HISTORIC PATIENT FINDINGS		ORD-1310401-01 VAF%
Blood Tumor Mutational Burden		1 Muts/Mb
Microsatellite status		MSI-High Not Detected
Tumor Fraction		18%
FGFR2	FGFR2-BICC1 fusion	28.1%
ARID1A	S460fs*163	12.2%
TP53	P151S	20.3%

NOTE This comparison table refers only to genes and biomarkers assayed by prior FoundationOne®Liquid CDx, FoundationOne®Liquid, FoundationOne®, or FoundationOne®CDx tests. Up to five previous tests may be shown.

For some genes in FoundationOne Liquid CDx, only select exons are assayed. Therefore, an alteration found by a previous test may not have been confirmed despite overlapping gene lists. Please refer to the Appendix for the complete list of genes and exons assayed. The gene and biomarker list will be updated periodically to reflect new knowledge about cancer biology.

As new scientific information becomes available, alterations that had previously been listed as Variants of Unknown Significance (VUS) may become reportable.

Tissue Tumor Mutational Burden (TMB) and blood TMB (bTMB) are estimated from the number of synonymous and non-synonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.

Not Tested = not baited, not reported on test, or test preceded addition of biomarker or gene

Not Detected = baited but not detected on test

Detected = present (VAF% is not applicable)

VAF% = variant allele frequency percentage

Cannot Be Determined = Sample is not of sufficient data quality to confidently determine biomarker status

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

BIOMARKER

Blood Tumor Mutational Burden

RESULT
1 Muts/Mb

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

On the basis of clinical evidence in NSCLC and HSNCC, increased bTMB may be associated with greater sensitivity to immunotherapeutic agents, including anti-PD-L1[1-2] and anti-PD-1[3] therapies. In NSCLC, multiple clinical trials have shown patients with higher bTMB derive clinical benefit from immune checkpoint inhibitors following single agent or combination treatments with either CTLA4 inhibitors or chemotherapy, with reported high bTMB cutpoints ranging from 6 to 16 Muts/Mb[1]. In HNSCC, a Phase 3 trial showed that bTMB ≥16 Muts/Mb (approximate equivalency ≥8 Muts/Mb as measured by this assay) was associated with improved survival from treatment with a PD-L1 inhibitor alone or in combination with a CTLA-4 inhibitor[4].

FREQUENCY & PROGNOSIS

Average bTMB levels in solid tumors other than NSCLC have not been evaluated (cBioPortal, COSMIC, PubMed, Mar 2022)[5-7]. Published data investigating the prognostic implications of bTMB levels in biliary tract cancer are limited (PubMed, Jul 2021). Although cases with hypermutated biliary tract cancer were enriched in a subgroup with poor prognosis in 1 study[8], TMB-high (≥10 mut/Mb) status in biliary adenocarcinoma not treated with immunotherapy was not significantly associated with OS in another study, in which patients with TMB-high tumors experienced numerically longer OS compared with patients with TMB-low tumors (11.5 vs. 8.4 months, adjusted HR=0.65)[9].

FINDING SUMMARY

Blood tumor mutational burden (bTMB, also known as mutation load) is a measure of the number of somatic protein-coding base substitution and insertion/deletion mutations from circulating tumor DNA in blood. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma[10-11] and cigarette smoke in lung cancer[12-13], treatment with temozolomide-based chemotherapy in glioma[14-15], mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes[16-20], and microsatellite instability (MSI)[16,19-20]. High bTMB levels were not detected in this sample. It is unclear whether the bTMB levels in this sample would be predicted to be associated with sensitivity to PD-1- or PD-L1-targeting immune checkpoint inhibitors, alone or in combination with other agents[1-3]. Depending on the clinical context, TMB testing of an alternate sample or by another methodology could be considered.

BIOMARKER

Tumor Fraction

RESULT
Elevated Tumor Fraction

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

Specimens with elevated tumor fraction have high circulating-tumor DNA (ctDNA) content, and thus high sensitivity for identifying genomic alterations. Such specimens are at low risk of false negative results. Tumor fraction levels currently have limited implications for diagnosis, surveillance, or therapy and should not be overinterpreted or compared from one blood draw to another. There are currently no targeted approaches to address specific tumor fraction levels. In the research setting, changes in tumor fraction estimates have been associated with treatment duration and clinical response and may be a useful indicator for future cancer management[21-26].

FREQUENCY & PROGNOSIS

Detectible ctDNA levels have been reported in a variety of tumor types, with higher tumor fraction levels reported for patients with metastatic (Stage 4) tumors compared with patients with localized disease (Stages 1 to 3)[27]. Elevated tumor fraction levels have been reported to be associated with worse prognosis in a variety of cancer types, including pancreatic cancer[28], Ewing sarcoma and osteosarcoma[29], prostate cancer[24], breast cancer[30], leiomyosarcoma[31], esophageal cancer[32], colorectal cancer[33], and gastrointestinal cancer[34].

FINDING SUMMARY

Tumor fraction provides an estimate of the percentage of ctDNA present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate for this sample is based on the observed level of aneuploid instability. The tumor fraction algorithm utilized for FoundationOne Liquid CDx uses the allele frequencies of approximately 1,000 single-nucleotide polymorphism (SNP) sites across the genome. Unlike the maximum somatic allele frequency (MSAF) method of estimating ctDNA content[35], the tumor fraction metric does not take into account the allele frequency of individual variants but rather produces a more holistic estimate of ctDNA content using data from across the genome. The amount of ctDNA detected may correlate with disease burden and response to therapy[36-37].

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
FGFR2

ALTERATION
FGFR2-BICC1 fusion

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

FGFR2 activating mutations, amplifications, or fusions may confer sensitivity to selective FGFR inhibitors such as erdafitinib[38], pemigatinib[39-40], infigratinib[41], E7090[42], AZD4547[43-45], Debio 1347[46-47], rogaratinib[48], futibatinib[49], ICP192[50], and derazantinib[51] as well as to the multikinase inhibitors pazopanib[52-53] and ponatinib[54]. In the context of FGFR2 rearrangement, FGFR inhibitors have primarily been investigated for patients with previously treated intrahepatic cholangiocarcinoma (ICC), with the Phase 2 FIGHT-202 trial for pemigatinib[40] and a Phase 2 trial for infigratinib[55] respectively reporting ORRs of 36% (38/107) and 23% (25/108). The Phase 2 FOENIX-CCA2 trial of futibatinib in locally advanced or metastatic, unresectable intrahepatic cholangiocarcinoma (ICC) harboring FGFR2 fusions or rearrangements reported a 42% (43/103) ORR, 83% (85/103) DCR, 9.7-month median duration of response, 9.0-month median PFS, and 21.7-month median OS[56]. A case series described 4 patients with FGFR2 fusion-positive ICC that exhibited PR (2) or SD (2) following treatment with futibatinib after initially progressing on infigratinib or Debio-1347; ctDNA analysis revealed the loss of FGFR2 kinase domain mutations while on futibatinib but also the emergence of additional mutations, including V564F (also known as V565F)[49]. A Phase 1/2 study of derazantinib for the treatment of FGFR2 fusion-positive inoperable ICC reported an ORR of 21% (6/29 PRs) and mPFS of 5.7 months[51].

FREQUENCY & PROGNOSIS

FGFR2 alterations, predominantly fusions, have been reported in 8-50% of intrahepatic cholangiocarcinomas[8,52,57-61]. In contrast, FGFR2 fusions were not identified in studies of patients with extrahepatic cholangiocarcinoma[8,62]. Although FGFR2 translocations were associated with favorable prognosis for patients with intrahepatic cholangiocarcinoma in 2 retrospective studies[57,63], no association was observed in 2 others[64-65]. In patients with cholangiocarcinoma harboring FGFR2 fusions, the presence of co-occurring mutations in CDKN2A/B, PBRM1, or TP53 was associated with significantly shorter PFS on pemigatinib (p=0.05)[66].

FINDING SUMMARY

FGFR2 encodes a tyrosine kinase cell surface receptor, which plays an important role in cell differentiation, growth, and angiogenesis[67-68]. FGFR2 fusions retaining the kinase domain encoded by exons 11-17 have been reported to be activating, oncogenic, and sensitive to FGFR inhibitors[59,69-71]. Furthermore, FGFR2 variants lacking a portion of the cytoplasmic domain encoded by exon 18 have been reported to be oncogenic in vitro[70-74]. Rearrangements such as observed here are predicted to be activating.

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
ARID1A

ALTERATION
S460fs*163

TRANSCRIPT ID
NM_006015

CODING SEQUENCE EFFECT
1377_1378insC

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no therapies approved to address the mutation or loss of ARID1A in cancer. However, on the basis of limited clinical and preclinical evidence, ARID1A inactivating mutations may lead to sensitivity to ATR inhibitors such as M6620 and ceralasertib[75]. In a Phase 2 study of ceralasertib in solid tumors, 2 patients with endometrial carcinoma in the cohort with loss of ARID1A expression achieved CRs on ceralasertib monotherapy; at least 1 of these 2 patients carried an inactivating ARID1A mutation. In contrast, no responses were observed for patients with normal ARID1A expression treated with ceralasertib combined with olaparib[76]. One patient with small cell lung cancer harboring an ARID1A mutation experienced a PR when treated with M6620 combined with topotecan[77]. In a Phase 1 trial, a patient with metastatic colorectal cancer harboring both an ARID1A mutation and ATM loss treated with single-agent M6620 achieved a CR that was ongoing at 29 months[78]. On the basis of limited preclinical evidence from studies in ovarian cancer, ARID1A inactivation may predict sensitivity to EZH2 inhibitors[79-80], which are under investigation in clinical trials. Other studies have reported that the loss of ARID1A may activate the PI3K-AKT pathway and be linked with sensitivity to inhibitors of this pathway[81-83]. Patients with ARID1A alterations in advanced or metastatic solid tumors may derive benefit from treatment with anti-PD-1 or anti-PD-L1 immunotherapy[84]. Loss of ARID1A expression has been associated with chemoresistance to platinum-based therapy for patients with ovarian clear cell carcinoma[85-86] and to 5-fluorouracil in colorectal cancer cell lines[87].

FREQUENCY & PROGNOSIS

ARID1A alterations are particularly prevalent in ovarian clear cell carcinoma (46-50%), ovarian and uterine endometrioid carcinomas (24-44%), and cholangiocarcinoma (27%); they are also reported in up to 27% of gastric carcinoma, esophageal adenocarcinoma, Waldenstrom macroglobulinemia, pediatric Burkitt lymphoma, hepatocellular carcinoma, colorectal carcinoma, and urothelial carcinoma samples analyzed (COSMIC, cBioPortal, Jan 2022)[5-7,58,88-92]. ARID1A loss is associated with microsatellite instability in ovarian and endometrial endometrioid adenocarcinomas[84,93-96], CRC[84,97-99], and gastric cancer[84,100-104]. ARID1A protein loss is associated with tumors of poor histological grade for many tumor types, including colorectal cancer (CRC)[97-99], cervical cancer[105-106], gastric cancer[100-104], urothelial carcinoma[107-109], ovarian and endometrial cancers[86,93-96,110-114], breast carcinoma[115-117], and clear cell renal cell carcinoma[118]; ARID1A mutation has been associated with poor outcomes for patients with cholangiocarcinoma[119-122]. However, prognostic data regarding patient survival are often mixed and conflicting.

FINDING SUMMARY

ARID1A encodes the AT-rich interactive domain-containing protein 1A, also known as Baf250a, a member of the SWI/SNF chromatin remodeling complex. Mutation, loss, or inactivation of ARID1A has been reported in many cancers, and the gene is considered a tumor suppressor[89,103,116,123-128]. ARID1A mutations, which are mostly truncating, have been identified along the entire gene and often correlate with ARID1A protein loss[89,101,124-125,129], whereas ARID1A missense mutations are mostly uncharacterized.

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

GENE
TP53

ALTERATION
P151S

TRANSCRIPT ID
NM_000546

CODING SEQUENCE EFFECT
451C>T

POTENTIAL TREATMENT STRATEGIES

— Targeted Therapies —

There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib[130-133], or p53 gene therapy and immunotherapeutics such as SGT-53[134-138] and ALT-801[139]. In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype[140]. A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum-refractory TP53-mutated ovarian, Fallopian tube, or peritoneal cancer[141]. A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum-refractory TP53-mutated ovarian cancer[142]. The combination of adavosertib with paclitaxel and carboplatin for patients with TP53-mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone[143]. In the Phase 2 VIKTORY trial, patients with TP53-mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel[144]. A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations[145]. The Phase 2 FOCUS4-C trial for patients with TP53- and RAS-mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring[146]. In a Phase 1b clinical trial of SGT-53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage[138]. Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR-246[147-149]. In a Phase 1b trial for patients with p53-positive high-grade serous ovarian cancer, APR-246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR[150]. ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies[151-152]; however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies[153-154]. Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition.

FREQUENCY & PROGNOSIS

Inactivation of p53, through mutation, deletion, or loss of heterozygosity (LOH), has been observed in 25-63% of gallbladder carcinomas and 10-61% of cholangiocarcinomas[8,57-58,61,128,155-159]. TP53 mutations occur more frequently in tumors caused by liver fluke (O. viverrini) infection (40%) than in cholangiocarcinoma cases not related to infection (9%)[128]. Aberrant TP53 expression, which is indicative of TP53 dysregulation, has been observed in 20–62% of gallbladder carcinomas and 25% (5/20) of cholangiocarcinomas[160-162]. Data regarding the prognostic significance of TP53 mutation in cholangiocarcinoma are conflicting[64,120-122,163-167]. Overexpression of p53 protein has been associated with reduced patient survival in poorly differentiated gallbladder adenocarcinomas and biliary tract cancers[168-169]; however, another study did not find such a correlation[164].

FINDING SUMMARY

Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers[170]. Alterations such as seen here may disrupt TP53 function or expression[171-175].

POTENTIAL GERMLINE IMPLICATIONS

One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li-Fraumeni syndrome (ClinVar, Sep 2021)[176]. Follow-up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li-Fraumeni syndrome and the early onset of many cancers[177-179], including sarcomas[180-181]. Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000[182] to 1:20,000[181]. For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30[183]. In the appropriate clinical context, germline testing of TP53 is recommended.

POTENTIAL CLONAL HEMATOPOIESIS IMPLICATIONS

Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age-related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion[184-189]. CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy[184-185]. Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease[190]. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH[188,191-192]. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Infigratinib

Assay findings association

FGFR2
FGFR2-BICC1 fusion

AREAS OF THERAPEUTIC USE

Infigratinib is a TKI that inhibits FGFR1, FGFR2, and FGFR3. It is FDA approved for the treatment of patients with unresectable locally advanced or metastatic cholangiocarcinoma who have FGFR2 rearrangements or fusions and have progressed after prior therapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

Based on clinical activity in cholangiocarcinoma[55], FGFR2 fusions or rearrangements may predict sensitivity to infigratinib.

SUPPORTING DATA

A Phase 2 study of single-agent infigratinib reported a 23.1% ORR (25/108; 1 CR, 24 PR), 5.0 month median duration of response, and 84.3% DCR (91/108) for patients with recurrent cholangiocarcinoma harboring an FGFR2 fusion or rearrangement; the median PFS and OS were 7.3 and 12.2 months, respectively[55].

Pemigatinib

Assay findings association

FGFR2
FGFR2-BICC1 fusion

AREAS OF THERAPEUTIC USE

Pemigatinib is FDA approved for the treatment of patients with advanced or metastatic cholangiocarcinoma who have FGFR2 rearrangements or fusions and have progressed after prior chemotherapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of strong clinical evidence and preclinical data for FGFR2 fusions, FGFR2 rearrangements may confer sensitivity to pemigatinib[39-40,193-195] .

SUPPORTING DATA

The Phase 2 FIGHT-202 study of pemigatinib for previously treated patients with FGFR2-rearranged advanced cholangiocarcinoma (CCA) reported a longer median OS (21.1 months vs. 6.7 vs. 4.0 months), longer median PFS (6.9 months vs. 2.1 vs. 1.7 months), and a higher ORR (36% [38/107, 3 CRs] vs. 0% vs. 0%) than those with or without FGF/FGFR alterations[40,66,195-196] . A Phase 1/2 FIGHT-101 study of pemigatinib for patients with FGFR-altered tumors reported 1 PR of 5.5 months for a patient with CCA and an FGFR2-CLIP1 fusion[39].

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

Erdafitinib

Assay findings association

FGFR2
FGFR2-BICC1 fusion

AREAS OF THERAPEUTIC USE

Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) inhibitor. It is FDA approved for the treatment of patients with advanced or metastatic urothelial carcinoma who have FGFR2 or FGFR3 alterations and have progressed after prior chemotherapy. Please see the drug label for full prescribing information.

GENE ASSOCIATION

On the basis of strong clinical evidence for FGFR2 fusions[38,197-198] , limited evidence for FGFR2 mutations[198-199] and limited evidence for FGFR2 amplification[200], and preclinical data[201-202] , FGFR2 activating alterations may confer sensitivity to erdafitinib.

SUPPORTING DATA

A Phase 2a study of erdafitinib for previously treated patients with FGFR-altered advanced cholangiocarcinoma (CCA) reported 47% (7/15) PRs and a median PFS of 5.6 months; for FGFR2- or FGFR3-fusion-positive CCA, there were 33% (6/9) PRs and a median PFS of 12.7 months[198]. A Phase 1 study for erdafitinib in solid tumors reported a better response in tumors carrying FGFR mutations or gene fusions compared to the overall cohort, with an ORR of 21% (19/92) vs 11% (21/187), respectively[200]. The most responsive tumor types for patients with FGFR mutations or fusions in this study were urothelial carcinoma and cholangiocarcinoma, with an ORR of 46% (12/26) and 27% (3/11), respectively; however, a patient with gallbladder carcinoma did not respond to erdafitinib in this study[200]. Of patients with FGFR altered CCA treated with erdafitinib in another Phase 1 study, including 1 patient with FGFR2 mutation and 2 patients with FGFR2 fusions, 27% (3/11) exhibited PRs; the median duration of response was 11.4 months, and an additional 27% (3/11) patients exhibited SD[199].

NOTE Genomic alterations detected may be associated with activity of certain US FDA or other specific country approved therapies; however, the therapies listed in this report may have varied evidence in the patient's tumor type. The listed therapies are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. The therapies listed in this report may not be complete and/or exhaustive. Furthermore, the listed therapies are limited to US FDA approved pharmaceutical drug products that are linked to a specific genomic alteration. There may also be US FDA approved pharmaceutical drug products that are not linked to a genomic alteration. Further there may also exist pharmaceutical drug products that are not approved by the US FDA or other national authorities. There may also be other treatment modalities available than pharmaceutical drug products.

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

IMPORTANT Clinical trials are ordered by gene and prioritized by: age range inclusion criteria for pediatric patients, proximity to ordering medical facility, later trial phase, and verification of trial information within the last two months. While every effort is made to ensure the accuracy of the information contained below, the information available in the public domain is continually updated and should be investigated by the physician or research staff. This is not a comprehensive list of all available clinical trials. There may also be compassionate use or early access programs available, which are not listed in this report. Foundation Medicine displays a subset of trial options and ranks them in this order of descending priority: Qualification for pediatric trial → Geographical proximity → Later trial phase. Clinical trials are not ranked in order of potential or predicted efficacy for this patient or in order of level of evidence for this patient's tumor type. Clinical trials listed here may have additional enrollment criteria that may require medical screening to determine final eligibility. For additional information about listed clinical trials or to conduct a search for additional trials, please see clinicaltrials.gov. However, clinicaltrials.gov does not list all clinical trials that might be available.

GENE
ARID1A

RATIONALE
ARID1A loss or inactivation may predict sensitivity to ATR inhibitors.

ALTERATION
S460fs*163

NCT04768296

PHASE 2

Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)

TARGETS
TOP1, ATR

LOCATIONS: Hangzhou (China), Nanjing (China), Wuhan (China), Xi'an (China), Osaka (Japan), Beijing (China), Hirakata-shi (Japan), Takatsuki-shi (Japan), Chengdu (China), Chuo-ku (Japan)

NCT02264678

PHASE 1/2

Ascending Doses of AZD6738 in Combination With Chemotherapy and/or Novel Anti Cancer Agents

TARGETS
ATR, PARP, PD-L1

LOCATIONS: Seongnam-si (Korea, Republic of), Seoul (Korea, Republic of), Goyang-si (Korea, Republic of), Cambridge (United Kingdom), Withington (United Kingdom), Manchester (United Kingdom), Coventry (United Kingdom), Sutton (United Kingdom), Oxford (United Kingdom), Villejuif (France)

NCT04657068

PHASE 1/2

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

TARGETS
ATR

LOCATIONS: London (United Kingdom), Colorado, Oklahoma, Tennessee, Florida

NCT04802174

PHASE 1/2

Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers

TARGETS
ATR

LOCATIONS: Maryland

NCT02595931

PHASE 1

ATR Kinase Inhibitor VX-970 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

TARGETS
ATR

LOCATIONS: California, Missouri, Pennsylvania, Massachusetts, Connecticut, Tennessee

NCT04514497

PHASE 1

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer

TARGETS
ATR, TOP1

LOCATIONS: Arizona, Oklahoma, Connecticut, Tennessee, Florida

NCT04266912

PHASE 1/2

Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors

TARGETS
ATR, PD-L1

LOCATIONS: Texas

NCT03669601

PHASE 1

AZD6738 & Gemcitabine as Combination Therapy

TARGETS
ATR

LOCATIONS: Cambridge (United Kingdom)

GENE
FGFR2

RATIONALE
FGFR inhibitors may be relevant in tumors with alterations that activate FGFR2.

ALTERATION
FGFR2-BICC1 fusion

NCT03773302

PHASE 3

Study of Oral Infigratinib in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

TARGETS
FGFR3, FGFR1, FGFR2

LOCATIONS: Taipei (Taiwan), Taoyuan City (Taiwan), Taichung City (Taiwan), Huwei (Taiwan), Tainan (Taiwan), Tainan City (Taiwan), Kaohsiung (Taiwan), Pusan (Korea, Republic of), Suwon-si (Korea, Republic of), Seongnam-si (Korea, Republic of)

NCT04083976

PHASE 2

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

TARGETS
FGFRs

LOCATIONS: Taipei (Taiwan), Taoyuan City (Taiwan), Taichung (Taiwan), Changhua (Taiwan), Tainan (Taiwan), Kaohsiung City (Taiwan), Kaohsiung (Taiwan), Hangzhou (China), Shanghai (China), Nanjing (China)

NCT04093362

PHASE 3

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

TARGETS
FGFRs

LOCATIONS: Taipei (Taiwan), Tainan (Taiwan), Kaohsiung (Taiwan), Busan (Korea, Republic of), Shatin (Hong Kong), Hong Kong (Hong Kong), Nagasaki-shi (Japan), Hwasun (Korea, Republic of), Fukuoka-shi (Japan), Daegu (Korea, Republic of)

NCT04238715

PHASE 2

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

TARGETS
FGFR1, FGFR2, FGFR3

LOCATIONS: Fuzhou (China), Xiamen (China), Ningbo (China), Hangzhou (China), Shanghai (China), Suzhou (China), Nantong (China), Shenzhen (China), Nanjing (China), Hefei (China)

NCT03656536

PHASE 3

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

TARGETS
FGFR1, FGFR2, FGFR3

LOCATIONS: Hangzhou (China), Shanghai (China), SHanghai (China), Nanjing (China), Yangzhou (China), Guangzhou (China), Wuhan (China), Fukuoka (Japan), Fukuoka-shi (Japan), Yufu-shi (Japan)

NCT05010668

PHASE 2

Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma

TARGETS
FGFRs, RET, PDGFRA, VEGFRs, KIT, PD-1

LOCATIONS: Shanghai (China)

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

NCT05010681

PHASE 2

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

TARGETS
PD-1, FGFRs, RET, PDGFRA, VEGFRs, KIT

LOCATIONS: Shanghai (China)

NCT04550624

PHASE 2

Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Cholangiocarcinoma

TARGETS
PD-1, KIT, VEGFRs, FGFRs, PDGFRA, RET

LOCATIONS: Shanghai (China)

NCT03758664

PHASE 1/2

Clinical Study of ICP-192 in Solid Tumors Patients

TARGETS
FGFR2, FGFR1, FGFR3, FGFR4

LOCATIONS: Shanghai (China)

NCT04189445

PHASE 2

Futibatinib in Patients With Specific FGFR Aberrations

TARGETS
FGFRs

LOCATIONS: Jordon (Hong Kong), Hong Kong (Hong Kong), Matsuyama-shi (Japan), Seongnam (Korea, Republic of), Seul (Korea, Republic of), Seoul (Korea, Republic of), Suita-shi (Japan), Nagoya-shi (Japan), Chuo-ku (Japan), Kashiwa-shi (Japan)

NOTE One or more variants of unknown significance (VUS) were detected in this patient's tumor. These variants may not have been adequately characterized in the scientific literature at the time this report was issued, and/or the genomic context of these alterations makes their significance unclear. We choose to include them here in the event that they become clinically meaningful in the future.

APC R94S	***CDK12*** T1161M	***CXCR4*** I142T	***GATA4*** A179_S180insA
MSH3 R296C	***TEK*** G743A	***TET2*** A1159P	

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

ABL1 **Exons 4-9**	*ACVR1B*	***AKT1*** **Exon 3**	*AKT2*	*AKT3*	***ALK*** **Exons 20-29, Introns 18, 19**	*ALOX12B*	*AMER1* (FAM123B)	***APC***
AR	***ARAF*** **Exons 4, 5, 7, 11, 13, 15, 16**	*ARFRP1*	*ARID1A*	*ASXL1*	***ATM***	***ATR***	*ATRX*	*AURKA*
AURKB	*AXIN1*	*AXL*	*BAP1*	*BARD1*	*BCL2*	*BCL2L1*	*BCL2L2*	*BCL6*
BCOR	*BCORL1*	*BCR** Introns 8, 13, 14	***BRAF*** **Exons 11-18,** Introns 7-10	***BRCA1*** Introns 2, 7, 8, 12, 16, 19, 20	***BRCA2*** Intron 2	*BRD4*	*BRIP1*	*BTG1*
BTG2	***BTK*** **Exons 2, 15**	*C11orf30* (EMSY)	*C17orf39* (GID4)	*CALR*	*CARD11*	*CASP8*	*CBFB*	*CBL*
CCND1	*CCND2*	*CCND3*	*CCNE1*	*CD22*	*CD70*	*CD74** Introns 6-8	*CD79A*	*CD79B*
CD274 **(PD-L1)**	*CDC73*	***CDH1***	***CDK12***	***CDK4***	***CDK6***	*CDK8*	*CDKN1A*	*CDKN1B*
CDKN2A	*CDKN2B*	*CDKN2C*	*CEBPA*	*CHEK1*	***CHEK2***	*CIC*	*CREBBP*	***CRKL***
CSF1R	*CSF3R*	*CTCF*	*CTNNA1*	***CTNNB1*** **Exon 3**	*CUL3*	*CUL4A*	*CXCR4*	*CYP17A1*
DAXX	*DDR1*	***DDR2*** **Exons 5, 17, 18**	*DIS3*	*DNMT3A*	*DOT1L*	*EED*	***EGFR*** **Introns 7,** 15**, 24-27**	*EP300*
EPHA3	*EPHB1*	*EPHB4*	***ERBB2***	***ERBB3*** **Exons 3, 6, 7, 8, 10, 12, 20, 21, 23, 24, 25**	*ERBB4*	*ERCC4*	*ERG*	***ERRFI1***
ESR1 **Exons 4-8**	*ETV4** Intron 8	*ETV5** Introns 6, 7	***ETV6**** **Introns 5, 6**	*EWSR1** Introns 7-13	***EZH2*** **Exons 4, 16, 17, 18**	*EZR** Introns 9-11	*FAM46C*	*FANCA*
FANCC	*FANCG*	*FANCL*	*FAS*	*FBXW7*	*FGF10*	*FGF12*	*FGF14*	*FGF19*
FGF23	*FGF3*	*FGF4*	*FGF6*	***FGFR1*** Introns 1, 5, **Intron 17**	***FGFR2*** Intron 1, **Intron 17**	***FGFR3*** **Exons 7, 9 (alternative designation exon 10), 14, 18, Intron 17**	*FGFR4*	*FH*
FLCN	*FLT1*	***FLT3*** **Exons 14, 15, 20**	***FOXL2***	*FUBP1*	*GABRA6*	*GATA3*	*GATA4*	*GATA6*
GNA11 **Exons 4, 5**	*GNA13*	***GNAQ*** **Exons 4, 5**	***GNAS*** **Exons 1, 8**	*GRM3*	*GSK3B*	*H3F3A*	*HDAC1*	*HGF*
HNF1A	***HRAS*** **Exons 2, 3**	*HSD3B1*	*ID3*	***IDH1*** **Exon 4**	***IDH2*** **Exon 4**	*IGF1R*	*IKBKE*	*IKZF1*
INPP4B	*IRF2*	*IRF4*	*IRS2*	*JAK1*	***JAK2*** **Exon 14**	***JAK3*** **Exons 5, 11, 12, 13, 15, 16**	*JUN*	*KDM5A*
KDM5C	*KDM6A*	*KDR*	*KEAP1*	*KEL*	***KIT*** **Exons 8, 9, 11, 12, 13, 17,** Intron 16	*KLHL6*	*KMT2A* (MLL) Introns 6, 8-11, Intron 7	*KMT2D* (MLL2)

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

APPENDIX Genes assayed in FoundationOne®Liquid CDx

FoundationOne Liquid CDx interrogates 324 genes, including 309 genes with complete exonic (coding) coverage and 15 genes with only select non-coding coverage (indicated with an *); 75 genes (indicated in bold) are captured with increased sensitivity and have complete exonic (coding) coverage unless otherwise noted.

KRAS	*LTK*	*LYN*	*MAF*	***MAP2K1*** **(MEK1) Exons 2, 3**	***MAP2K2*** **(MEK2) Exons 2-4, 6, 7**	*MAP2K4*	*MAP3K1*	*MAP3K13*
MAPK1	*MCL1*	***MDM2***	*MDM4*	*MED12*	*MEF2B*	*MEN1*	*MERTK*	***MET***
MITF	*MKNK1*	*MLH1*	***MPL*** **Exon 10**	*MRE11A*	*MSH2* Intron 5	*MSH3*	*MSH6*	*MST1R*
MTAP	***MTOR*** **Exons 19, 30, 39, 40, 43-45, 47, 48, 53, 56**	*MUTYH*	*MYB** Intron 14	***MYC*** **Intron 1**	*MYCL* (MYCL1)	***MYCN***	***MYD88*** **Exon 4**	*NBN*
NF1	*NF2*	*NFE2L2*	*NFKBIA*	*NKX2-1*	*NOTCH1*	*NOTCH2* Intron 26	*NOTCH3*	***NPM1*** **Exons 4-6, 8, 10**
NRAS **Exons 2, 3**	*NSD3* (WHSC1L1)	*NT5C2*	***NTRK1*** **Exons 14, 15, Introns 8-11**	*NTRK2* Intron 12	***NTRK3*** **Exons 16, 17**	*NUTM1** Intron 1	*P2RY8*	***PALB2***
PARK2	*PARP1*	*PARP2*	*PARP3*	*PAX5*	*PBRM1*	*PDCD1* (PD-1)	***PDCD1LG2*** **(PD-L2)**	***PDGFRA*** **Exons 12, 18, Introns 7, 9, 11**
PDGFRB **Exons 12-21, 23**	*PDK1*	*PIK3C2B*	*PIK3C2G*	***PIK3CA*** **Exons 2, 3, 5-8, 10, 14, 19, 21 (Coding Exons 1, 2, 4-7, 9, 13, 18, 20)**	*PIK3CB*	*PIK3R1*	*PIM1*	*PMS2*
POLD1	*POLE*	*PPARG*	*PPP2R1A*	*PPP2R2A*	*PRDM1*	*PRKAR1A*	*PRKCI*	*PTCH1*
PTEN	***PTPN11***	*PTPRO*	*QKI*	*RAC1*	*RAD21*	*RAD51*	*RAD51B*	*RAD51C*
RAD51D	*RAD52*	*RAD54L*	***RAF1*** **Exons 3, 4, 6, 7, 10, 14, 15, 17,** Introns 4-8	*RARA* Intron 2	***RB1***	*RBM10*	*REL*	***RET*** Introns 7, 8, **Exons 11, 13-16, Introns 9-11**
RICTOR	*RNF43*	***ROS1*** **Exons 31, 36-38, 40, Introns 31-35**	*RPTOR*	*RSPO2** Intron 1	*SDC4** Intron 2	*SDHA*	*SDHB*	*SDHC*
SDHD	*SETD2*	*SF3B1*	*SGK1*	*SLC34A2** Intron 4	*SMAD2*	*SMAD4*	*SMARCA4*	*SMARCB1*
SMO	*SNCAIP*	*SOCS1*	*SOX2*	*SOX9*	*SPEN*	*SPOP*	*SRC*	*STAG2*
STAT3	***STK11***	*SUFU*	*SYK*	*TBX3*	*TEK*	*TERC** ncRNA	***TERT**** **Promoter**	*TET2*
TGFBR2	*TIPARP*	*TMPRSS2** Introns 1-3	*TNFAIP3*	*TNFRSF14*	***TP53***	*TSC1*	*TSC2*	*TYRO3*
U2AF1	***VEGFA***	*VHL*	*WHSC1*	*WT1*	*XPO1*	*XRCC2*	*ZNF217*	*ZNF703*

ADDITIONAL ASSAYS: FOR THE DETECTION OF SELECT CANCER BIOMARKERS

Microsatellite (MS) status

Blood Tumor Mutational Burden (bTMB)

Tumor Fraction

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

FoundationOne Liquid CDx fulfills the requirements of the European Directive 98/79 EC for in vitro diagnostic medical devices and is registered as a CE-IVD product by Foundation Medicine's EU Authorized Representative, Qarad b.v.b.a, Cipalstraat 3, 2440 Geel, Belgium. The CE-IVD regulatory status of FoundationOne Liquid CDx is applicable in countries that accept and/or recognize the CE mark.

CE IVD

ABOUT FOUNDATIONONE LIQUID CDx

FoundationOne Liquid CDx was developed and its performance characteristics determined by Foundation Medicine, Inc. (Foundation Medicine). FoundationOne Liquid CDx may be used for clinical purposes and should not be regarded as purely investigational or for research only. Foundation Medicine's clinical reference laboratories are qualified to perform high-complexity clinical testing.

Please refer to technical information for performance specification details.

INTENDED USE

FoundationOne Liquid CDx is a next generation sequencing based **in vitro** diagnostic device that analyzes 324 genes. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The test also detects the genomic signatures blood tumor mutational burden (bTMB), microsatellite instability (MSI), and tumor fraction. FoundationOne Liquid CDx utilizes circulating cell-free DNA (cfDNA) isolated from plasma derived from the anti-coagulated peripheral whole blood of cancer patients. The test is intended to be used as a companion diagnostic to identify patients who may benefit from treatment with targeted therapies in accordance with the approved therapeutic product labeling. Additionally, FoundationOne Liquid CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with malignant neoplasms.

TEST PRINCIPLES

The FoundationOne Liquid CDx assay is performed exclusively as a laboratory service using circulating cell-free DNA (cfDNA) isolated from plasma derived from anti-coagulated peripheral whole blood from patients with solid malignant neoplasms. The assay employs a single DNA extraction method to obtain cfDNA from plasma from whole blood. Extracted cfDNA undergoes whole-genome shotgun library construction and hybridization-based capture of 324 cancer-related genes including coding exons and select introns of 309 genes, as well as only select intronic regions or non-coding regions of 15 genes. Hybrid-capture selected libraries are sequenced with deep coverage using the NovaSeq® 6000 platform. Sequence data are processed using a customized analysis pipeline designed to accurately detect genomic alterations, including base substitutions, indels, select copy number variants, and select genomic rearrangements. Substitutions and insertion and deletion alterations (indels) are reported in 311 genes, copy number alterations (CNAs) are reported in 310 genes, and gene rearrangements are reported in 324 genes. The assay also reports tumor fraction, and genomic signatures including MSI and bTMB. A subset of targeted regions in 75 genes is baited for increased sensitivity.

THE REPORT

Incorporates analyses of peer-reviewed studies and other publicly available information identified by Foundation Medicine; these analyses and information may include associations between a molecular alteration (or lack of alteration) and one or more drugs with potential clinical benefit (or potential lack of clinical benefit), including drug candidates that are being studied in clinical research. **Note:** A finding of biomarker alteration does not necessarily indicate pharmacologic effectiveness (or lack thereof) of any drug or treatment regimen; a finding of no biomarker alteration does not necessarily indicate lack of pharmacologic effectiveness (or effectiveness) of any drug or treatment regimen.

QUALIFIED ALTERATION CALLS (EQUIVOCAL)

All equivocal calls, regardless of alteration type, imply that there is adequate evidence to call the alteration with confidence. However, the repeatability of equivocal calls may be lower than non-equivocal calls.

RANKING OF THERAPIES AND CLINICAL TRIALS

Ranking of Therapies in Summary Table

Therapies are ranked based on the following criteria: Therapies with clinical benefit (ranked alphabetically within each evidence category), followed by therapies associated with resistance (when applicable).

Ranking of Clinical Trials

Pediatric trial qualification → Geographical proximity → Later trial phase.

LIMITATIONS

1. For **in vitro** diagnostic use.
2. For prescription use only. This test must be ordered by a qualified medical professional in accordance with clinical laboratory regulations.
3. A negative result does not rule out the presence of a mutation below the limits of detection of the assay. Patients for whom no companion diagnostic alterations are detected should be considered for confirmation with an appropriately validated tumor tissue test, if available.
4. The FoundationOne Liquid CDx assay does not detect heterozygous deletions.
5. The test is not intended to provide information on cancer predisposition.
6. Performance has not been validated for cfDNA input below the specified minimum input.
7. Tissue TMB and blood TMB (bTMB) are estimated from the number of synonymous and nonsynonymous single-nucleotide variants (SNVs) and insertions and deletions (indels) per area of coding genome sampled, after the removal of known and likely oncogenic driver events and germline SNPs. Tissue TMB is calculated based on variants with an allele frequency of ≥5%, and bTMB is calculated based on variants with an allele frequency of ≥0.5%.
8. Tumor fraction is the percentage of circulating tumor DNA (ctDNA) present in a cell-free DNA (cfDNA) sample. The tumor fraction estimate is computationally derived from the observed level of aneuploidy in the sample. Tumor fraction is considered elevated when ctDNA levels are high enough that aneuploidy can be detected and is significantly distinct from that typically found in non-tumor samples.
9. Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the tumor genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor. The MSI algorithm is based on genome wide analysis of 1765 microsatellite loci and not based on the 5 or 7 MSI loci described in current clinical practice guidelines for solid tissue testing.
10. Genomic findings from circulating cell-free DNA (cfDNA) may originate from circulating tumor DNA fragments, germline alterations, or non-tumor somatic alterations, such as clonal hematopoiesis of indeterminate potential (CHIP). Genes with alterations that may be derived from CHIP include, but are not limited

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

to: **ASXL1** , **ATM** , **CBL** , **CHEK2** , **DNMT3A** , **JAK2** , **KMT2D** (**MLL2**), **MPL** , **MYD88** , **SF3B1** , **TET2** , **TP53** , and **U2AF1** .

11. Alterations reported may include somatic (not inherited) or germline (inherited) alterations; however, the test does not distinguish between germline and somatic alterations. If a reported alteration is suspected to be germline, confirmatory testing should be considered in the appropriate clinical context.
12. The test is not intended to replace germline testing or to provide information about cancer predisposition.

REPORT HIGHLIGHTS

The Report Highlights includes select genomic and therapeutic information with potential impact on patient care and treatment that is specific to the genomics and tumor type of the sample analyzed. This section may highlight information including targeted therapies with potential sensitivity or resistance; evidence-matched clinical trials; and variants with potential diagnostic, prognostic, nontargeted treatment, germline, or clonal hematopoiesis implications. Information included in the Report Highlights is expected to evolve with advances in scientific and clinical research. Findings included in the Report Highlights should be considered in the context of all other information in this report and other relevant patient information. Decisions on patient care and treatment are the responsibility of the treating physician.

VARIANTS TO CONSIDER FOR FOLLOW-UP GERMLINE TESTING

The variants indicated for consideration of follow-up germline testing are 1) limited to reportable short variants with a protein effect listed in the ClinVar genomic database (Landrum et al., 2018; 29165669) as Pathogenic, Pathogenic/Likely Pathogenic, or Likely Pathogenic (by an expert panel or multiple submitters), 2) associated with hereditary cancer-predisposing disorder(s), 3) detected at an allele frequency of >30%, and 4) in select genes reported by the ESMO Precision Medicine Working Group (Mandelker et al., 2019; 31050713) to have a greater than 10% probability of germline origin if identified during tumor sequencing. The selected genes are *ATM, BAP1, BRCA1, BRCA2, BRIP1, CHEK2, FH, FLCN, MLH1, MSH2, MSH6, MUTYH, PALB2, PMS2, POLE, RAD51C, RAD51D, RET, SDHA, SDHB, SDHC, SDHD, TSC2,* and *VHL*, and are not inclusive of all cancer susceptibility genes. The content in this report should not substitute for genetic counseling or follow-up germline testing, which is needed to distinguish whether a finding in this patient's tumor sequencing is germline or somatic. Interpretation should be based on clinical context.

VARIANTS THAT MAY REPRESENT CLONAL HEMATOPOIESIS

Variants that may represent clonal hematopoiesis (CH) are limited to select reportable short variants in defined genes identified in solid tumors only. Variant selection was determined based on gene tumor-suppressor or oncogene status, known role in solid tumors versus hematological malignancies, and literature prevalence. The defined genes are *ASXL1, ATM, CBL, CHEK2, DNMT3A, IDH2, JAK2, KMT2D (MLL2), MPL, MYD88, SF3B1, TET2,* and *U2AF1* and are not inclusive of all CH genes. The content in this report should not substitute for dedicated hematological workup. Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH. Patient-matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH. Interpretation should be based on clinical context.

NATIONAL COMPREHENSIVE CANCER NETWORK® (NCCN®) CATEGORIZATION

Biomarker and genomic findings detected may be associated with certain entries within the NCCN Drugs & Biologics Compendium® (NCCN Compendium®) (www.nccn.org). The NCCN Categories of Evidence and Consensus indicated reflect the highest possible category for a given therapy in association with each biomarker or genomic finding. Please note, however, that the accuracy and applicability of these NCCN categories within a report may be impacted by the patient's clinical history, additional biomarker information, age, and/or co-occurring alterations. For additional information on the NCCN categories, please refer to the NCCN Compendium®. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

LEVEL OF EVIDENCE NOT PROVIDED

Drugs with potential clinical benefit (or potential lack of clinical benefit) are not evaluated for source or level of published evidence.

NO GUARANTEE OF CLINICAL BENEFIT

This report makes no promises or guarantees that a particular drug will be effective in the treatment of disease in any patient. This report also makes no promises or guarantees that a drug with potential lack of clinical benefit will in fact provide no clinical benefit.

NO GUARANTEE OF REIMBURSEMENT

Foundation Medicine makes no promises or guarantees that a healthcare provider, insurer or other third party payor, whether private or governmental, will reimburse a patient for the cost of FoundationOne Liquid CDx.

TREATMENT DECISIONS ARE THE RESPONSIBILITY OF PHYSICIAN

Drugs referenced in this Report may not be suitable for a particular patient. The selection of any, all or none of the drugs associated with potential clinical benefit (or potential lack of clinical benefit) resides entirely within the discretion of the treating physician. Indeed, the information in this Report must be considered in conjunction with all other relevant information regarding a particular patient, before the patient's treating physician recommends a course of treatment. Decisions on patient care and treatment must be based on the independent medical judgment of the treating physician, taking into consideration all applicable information concerning the patient's condition, such as patient and family history, physical examinations, information from other diagnostic tests, and patient preferences, in accordance with the standard of care in a given community. A treating physician's decisions should not be based on a single test, such as this test or the information contained in this report.

Certain sample of variant characteristics may result in reduced sensitivity. These include: low sample quality, deletions and insertions >40bp, or repetitive/high homology sequences. FoundationOne Liquid CDx is performed using cell-free DNA, and as such germline events may not be reported.

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

SELECT ABBREVIATIONS

ABBREVIATION	DEFINITION
CR	Complete response
DCR	Disease control rate
DNMT	DNA methyltransferase
HR	Hazard ratio
ITD	Internal tandem duplication
MMR	Mismatch repair
Muts/Mb	Mutations per megabase
NOS	Not otherwise specified
ORR	Objective response rate
OS	Overall survival
PD	Progressive disease
PFS	Progression-free survival
PR	Partial response
SD	Stable disease
TKI	Tyrosine kinase inhibitor

MR Suite Version 6.0.0

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

1. Gandara DR, et al. Nat. Med. (2018) pmid: 30082870
2. Wang Z, et al. JAMA Oncol (2019) pmid: 30816954
3. Aggarwal C, et al. Clin. Cancer Res. (2020) pmid: 32102950
4. Li et al., 2020; ASCO Abstract 6511
5. Cerami E, et al. Cancer Discov (2012) pmid: 22588877
6. Gao J, et al. Sci Signal (2013) pmid: 23550210
7. Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878
8. Nakamura H, et al. Nat. Genet. (2015) pmid: 26258846
9. Shao C, et al. JAMA Netw Open (2020) pmid: 33119110
10. Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635
11. Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803
12. Pfeifer GP, et al. Oncogene (2002) pmid: 12379884
13. Rizvi NA, et al. Science (2015) pmid: 25765070
14. Johnson BE, et al. Science (2014) pmid: 24336570
15. Choi S, et al. Neuro-oncology (2018) pmid: 29452419
16. Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398
17. Briggs S, et al. J. Pathol. (2013) pmid: 23447401
18. Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393
19. Nature (2012) pmid: 22810696
20. Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919
21. Bronkhorst AJ, et al. Biomol Detect Quantif (2019) pmid: 30923679
22. Raja R, et al. Clin. Cancer Res. (2018) pmid: 30093454
23. Hrebien S, et al. Ann. Oncol. (2019) pmid: 30860573
24. Choudhury AD, et al. JCI Insight (2018) pmid: 30385733
25. Goodall J, et al. Cancer Discov (2017) pmid: 28450425
26. Goldberg SB, et al. Clin. Cancer Res. (2018) pmid: 29330207
27. Bettegowda C, et al. Sci Transl Med (2014) pmid: 24553385
28. Lapin M, et al. J Transl Med (2018) pmid: 30400802
29. Shulman DS, et al. Br. J. Cancer (2018) pmid: 30131550
30. Stover DG, et al. J. Clin. Oncol. (2018) pmid: 29298117
31. Hemming ML, et al. JCO Precis Oncol (2019) pmid: 30793095
32. Egyud M, et al. Ann. Thorac. Surg. (2019) pmid: 31059681
33. Fan G, et al. PLoS ONE (2017) pmid: 28187169
34. Vu et al., 2020; DOI: 10.1200/PO.19.00204
35. Li G, et al. J Gastrointest Oncol (2019) pmid: 31602320
36. Zhang EW, et al. Cancer (2020) pmid: 32757294
37. Butler TM, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 30833418
38. Tabernero J, et al. J. Clin. Oncol. (2015) pmid: 26324363
39. Krook MA, et al. Cold Spring Harb Mol Case Stud (2019) pmid: 31371345
40. Abou-Alfa GK, et al. Lancet Oncol. (2020) pmid: 32203698
41. Nogova L, et al. J. Clin. Oncol. (2017) pmid: 27870574
42. Morizane et al., 2020; ASCO GI Abstract 538
43. Pearson A, et al. Cancer Discov (2016) pmid: 27179038
44. Van Cutsem E, et al. Ann. Oncol. (2017) pmid: 29177434
45. Aggarwal C, et al. J Thorac Oncol (2019) pmid: 31195180
46. Voss MH, et al. Clin. Cancer Res. (2019) pmid: 30745300
47. Cleary JM, et al. Cancer Discov (2021) pmid: 33926920
48. Schuler M, et al. Lancet Oncol. (2019) pmid: 31405822
49. Goyal L, et al. Cancer Discov (2019) pmid: 31109923
50. Guo et al., 2021; ASCO Abstract 4092
51. Mazzaferro V, et al. Br. J. Cancer (2019) pmid: 30420614
52. Borad MJ, et al. PLoS Genet. (2014) pmid: 24550739
53. Liao RG, et al. Cancer Res. (2013) pmid: 23786770
54. Gozgit JM, et al. Mol. Cancer Ther. (2012) pmid: 22238366
55. Javle et al., 2021; ASCO GI Abstract 265
56. Goyal et al., 2021; AACR Abstract CT010
57. Javle M, et al. Cancer (2016) pmid: 27622582
58. Ross JS, et al. Oncologist (2014) pmid: 24563076
59. Arai Y, et al. Hepatology (2014) pmid: 24122810
60. Sia D, et al. Nat Commun (2015) pmid: 25608663
61. Jiao Y, et al. Nat. Genet. (2013) pmid: 24185509
62. Lee H, et al. J. Clin. Pathol. (2016) pmid: 26500333
63. Graham RP, et al. Hum Pathol (2014) pmid: 24837095
64. Boerner T, et al. Hepatology (2021) pmid: 33765338
65. Pu X, et al. Pathol Res Pract (2020) pmid: 32825971
66. Silverman IM, et al. Cancer Discov (2021) pmid: 33218975
67. Powers CJ, et al. Endocr. Relat. Cancer (2000) pmid: 11021964
68. Turner N, et al. Nat. Rev. Cancer (2010) pmid: 20094046
69. Singh D, et al. Science (2012) pmid: 22837387
70. Lorenzi MV, et al. Proc. Natl. Acad. Sci. U.S.A. (1996) pmid: 8799135
71. Wu YM, et al. Cancer Discov (2013) pmid: 23558953
72. Lorenzi MV, et al. Oncogene (1997) pmid: 9266968
73. Ueda T, et al. Cancer Res. (1999) pmid: 10626794
74. Cha JY, et al. J. Biol. Chem. (2009) pmid: 19103595
75. Williamson CT, et al. Nat Commun (2016) pmid: 27958275
76. Aggarwal et al., 2021; ESMO Abstract 5120
77. Thomas A, et al. J. Clin. Oncol. (2018) pmid: 29252124
78. Yap TA, et al. J Clin Oncol (2020) pmid: 32568634
79. Bitler BG, et al. Nat. Med. (2015) pmid: 25686104
80. Kim KH, et al. Nat. Med. (2015) pmid: 26552009
81. Wiegand KC, et al. BMC Cancer (2014) pmid: 24559118
82. Huang HN, et al. Mod. Pathol. (2014) pmid: 24336158
83. Samartzis EP, et al. Oncotarget (2014) pmid: 24979463
84. Okamura R, et al. J Immunother Cancer (2020) pmid: 32111729
85. Yokoyama Y, et al. J Gynecol Oncol (2014) pmid: 24459582
86. Katagiri A, et al. Mod. Pathol. (2012) pmid: 22101352
87. Xie C, et al. Tumour Biol. (2014) pmid: 24833095
88. Wu RC, et al. Cancer Biol. Ther. (2014) pmid: 24618703
89. Jones S, et al. Hum. Mutat. (2012) pmid: 22009941
90. Dulak AM, et al. Nat. Genet. (2013) pmid: 23525077
91. Streppel MM, et al. Oncogene (2014) pmid: 23318448
92. Jiao Y, et al. J. Pathol. (2014) pmid: 24293293
93. Huang HN, et al. Histopathology (2015) pmid: 25195947
94. Hussein YR, et al. Mod. Pathol. (2015) pmid: 25394778
95. Bosse T, et al. Mod. Pathol. (2013) pmid: 23702729
96. Allo G, et al. Mod. Pathol. (2014) pmid: 23887303
97. Chou A, et al. Hum. Pathol. (2014) pmid: 24925223
98. Ye J, et al. Hum. Pathol. (2014) pmid: 25311944
99. Wei XL, et al. World J. Gastroenterol. (2014) pmid: 25561809
100. Chen K, et al. Proc. Natl. Acad. Sci. U.S.A. (2015) pmid: 25583476
101. Wang K, et al. Nat. Genet. (2011) pmid: 22037554
102. Abe H, et al. Virchows Arch. (2012) pmid: 22915242
103. Wang DD, et al. PLoS ONE (2012) pmid: 22808142
104. Wiegand KC, et al. Hum. Pathol. (2014) pmid: 24767857
105. Katagiri A, et al. Int. J. Gynecol. Cancer (2012) pmid: 22274316
106. Cho H, et al. Hum. Pathol. (2013) pmid: 23427874
107. Gui Y, et al. Nat. Genet. (2011) pmid: 21822268
108. Balbás-Martínez C, et al. PLoS ONE (2013) pmid: 23650517
109. Faraj SF, et al. Hum. Pathol. (2014) pmid: 25175170
110. Rahman M, et al. Hum. Pathol. (2013) pmid: 22939958
111. Maeda D, et al. Int J Mol Sci (2010) pmid: 21614196
112. Lowery WJ, et al. Int. J. Gynecol. Cancer (2012) pmid: 22193641
113. Fadare O, et al. Mod. Pathol. (2013) pmid: 23524907
114. Mao TL, et al. Am. J. Surg. Pathol. (2013) pmid: 24076775
115. Zhang X, et al. Cancer Epidemiol (2012) pmid: 21889920
116. Mamo A, et al. Oncogene (2012) pmid: 21892209
117. Zhao J, et al. Tumour Biol. (2014) pmid: 24430365
118. Lichner Z, et al. Am. J. Pathol. (2013) pmid: 23416164
119. Feng F, et al. Int J Clin Oncol (2021) pmid: 33387086
120. Conci S, et al. Updates Surg (2020) pmid: 32020551
121. Simbolo M, et al. Sci Rep (2018) pmid: 29740198
122. Ruzzenente A, et al. Ann. Surg. Oncol. (2016) pmid: 26717940
123. Guan B, et al. Cancer Res. (2011) pmid: 21900401
124. Wiegand KC, et al. N. Engl. J. Med. (2010) pmid: 20942669
125. Jones S, et al. Science (2010) pmid: 20826764
126. Yan HB, et al. Carcinogenesis (2014) pmid: 24293408
127. Huang J, et al. Nat. Genet. (2012) pmid: 22922871
128. Chan-On W, et al. Nat. Genet. (2013) pmid: 24185513
129. Zang ZJ, et al. Nat. Genet. (2012) pmid: 22484628
130. Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315
131. Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033
132. Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100
133. Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633
134. Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850
135. Xu L, et al. Mol. Med. (2001) pmid: 11713371
136. Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564
137. Kim SS, et al. Nanomedicine (2015) pmid: 25240597
138. Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628
139. Hajdenberg et al., 2012; ASCO Abstract e15010
140. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554
141. Moore et al., 2019; ASCO Abstract 5513
142. Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224
143. Oza et al., 2015; ASCO Abstract 5506
144. Lee J, et al. Cancer Discov (2019) pmid: 31315834
145. Méndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125
146. Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072
147. Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953
148. Mohell N, et al. Cell Death Dis (2015) pmid: 26086967
149. Fransson Å, et al. J Ovarian Res (2016) pmid: 27179933
150. Gourley et al., 2016; ASCO Abstract 5571
151. Kwok M, et al. Blood (2016) pmid: 26563132
152. Boudny M, et al. Haematologica (2019) pmid: 30975914
153. Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704
154. Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241
155. Li M, et al. Nat. Genet. (2014) pmid: 24997986
156. Borger DR, et al. Oncologist (2012) pmid: 22180306
157. Suto T, et al. J Surg Oncol (2000) pmid: 10738270
158. Ong CK, et al. Nat. Genet. (2012) pmid: 22561520
159. Nault JC, et al. Semin. Liver Dis. (2011) pmid: 21538283
160. Won HS, et al. BMC Cancer (2010) pmid: 20955617
161. Chaube A, et al. BMC Cancer (2006) pmid: 16686942
162. Chuang SC, et al. World J Surg (2004) pmid: 15573254

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531

163. Xiaofang L, et al. World J Surg Oncol (2012) pmid: 22230750
164. Ajiki T, et al. Hepatogastroenterology () pmid: 8799388
165. J Surg Oncol (2006) pmid: 16724348
166. Guo R, et al. Hum. Pathol. (2014) pmid: 24746206
167. Churi CR, et al. PLoS ONE (2014) pmid: 25536104
168. Lee CS, et al. Pathology (1995) pmid: 7567135
169. Ahrendt SA, et al. J Hepatobiliary Pancreat Surg (2000) pmid: 11180865
170. Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675
171. Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249
172. Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609
173. Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130
174. Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496
175. Yamada H, et al. Carcinogenesis (2007) pmid: 17690113
176. Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669
177. Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290
178. Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100
179. Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776
180. Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316
181. Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208
182. Lalloo F, et al. Lancet (2003) pmid: 12672316
183. Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713
184. Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837
185. Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838
186. Xie M, et al. Nat. Med. (2014) pmid: 25326804
187. Acuna-Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404
188. Severson EA, et al. Blood (2018) pmid: 29678827
189. Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212
190. Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320
191. Chabon JJ, et al. Nature (2020) pmid: 32269342
192. Razavi P, et al. Nat. Med. (2019) pmid: 31768066
193. Vogel et al. 2019; ESMO Abstract LBA40
194. Bibeau et al. 2020; ASCO GI Abstract 588
195. Hollebecque et al., 2019; ESMO Abstract 720P
196. Vogel et al., 2019; ESMO abstract LBA40
197. Siefker-Radtke et al., 2018; ASCO Abstract 4503
198. Park et al., 2019; ASCO Abstract 4117
199. Soria et al., 2017; ASCO Abstract 4074
200. Bahleda R, et al. Clin. Cancer Res. (2019) pmid: 31088831
201. Perera TPS, et al. Mol. Cancer Ther. (2017) pmid: 28341788
202. Karkera JD, et al. Mol. Cancer Ther. (2017) pmid: 28416604

Electronically signed by Eric Severson, M.D., Ph.D., M.M.Sc. | 06 March 2022
Julia Elvin, M.D., Ph.D., Laboratory Director CLIA: 22D2027531
Nimesh R. Patel, M.D., Laboratory Director CLIA: 34D2044309
Foundation Medicine, Inc. · 1.888.988.3639

Sample Analysis: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Sample Preparation: 150 Second St., 1st Floor, Cambridge, MA 02141 · CLIA: 22D2027531
Post-Sequencing Analysis: 150 Second St., 1st Floor. Cambridge, MA 02141 · CLIA: 22D2027531